keyword
MENU ▼
Read by QxMD icon Read
search

Prescription drug pricing

keyword
https://www.readbyqxmd.com/read/28721311/from-kaua-i-to-hawai-i-island-interisland-differences-in-emergency-contraceptive-pill-availability
#1
Holly Bullock, Mary Tschann, Jennifer Elia, Bliss Kaneshiro, Jennifer Salcedo
Emergency contraceptive pills (ECPs) are medications used after unprotected intercourse, underprotected intercourse, or sexual assault to decrease the risk of pregnancy. Availability of ECPs in Hawai'i's retail pharmacies was last assessed in 2007, following over-the-counter access to levonorgestrel ECPs (LNG-ECP) for women age 18 years or older and prior to U.S. Food and Drug Administration (FDA) approval of prescription-only ulipristal acetate (UPA). We conducted a county-by-county subanalysis from a larger observational population-based study on statewide availability of ECPs in Hawai'i's pharmacies...
July 2017: Hawai'i Journal of Medicine & Public Health: a Journal of Asia Pacific Medicine & Public Health
https://www.readbyqxmd.com/read/28707550/rising-cost-of-anticancer-medications-in-the-united-states
#2
Kristy Jackson, Milap C Nahata
With more than 1.6 million new cases of cancer occurring each year, anticancer medications are in high demand. Escalating prescription drug prices have become a significant concern. Anticancer medications are among the most expensive prescription medications, many of them exceeding $100 000 a year. The survival benefits of certain newer anticancer medications may be a few months more than that from the existing treatment but at a much higher price tag. Drug cost may play a substantial role in making treatment choices...
August 2017: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/28700190/getting-to-the-root-of-high-prescription-drug-prices
#3
Henry Waxman, Bill Corr, Kristi Martin, Sophia Duong
ISSUE: Historic increases in prescription drug prices and spending are contributing to unsustainable health care costs in the United States. There is widespread public support for elected officials to address the problem. GOAL: To document the drivers of high U.S. prescription drug prices and offer a broad range of feasible policy actions. METHODS: Interviews with experts and organizations engaged with prescription drug development and utilization, pricing, regulation, and clinical practice. Review of policy documents, proposals, and position statements from a variety of stakeholders...
July 2017: Issue Brief of the Commonwealth Fund
https://www.readbyqxmd.com/read/28692713/value-based-pricing-and-state-reform-of-prescription-drug-costs
#4
Thomas J Hwang, Aaron S Kesselheim, Ameet Sarpatwari
No abstract text is available yet for this article.
July 10, 2017: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/28672324/high-generic-drug-prices-and-market-competition-a-retrospective-cohort-study
#5
Chintan V Dave, Aaron S Kesselheim, Erin R Fox, Peihua Qiu, Abraham Hartzema
Background: Prices for some generic drugs have increased in recent years, adversely affecting patients who rely on them. Objective: To determine the association between market competition levels and the change in generic drug prices in the United States. Design: Retrospective cohort study. Setting: Prescription claims from commercial health plans between 2008 and 2013. Measurements: The 5.5 years of data were divided into 11 study periods of 6 months each...
July 4, 2017: Annals of Internal Medicine
https://www.readbyqxmd.com/read/28670678/the-economic-burden-of-opioid-prescription-by-dentists-a-12-month-survey-of-consumer-expenditure-in-brazil
#6
Tulio Eduardo Nogueira, Patrícia Azevedo Lino, Maria Auxiliadora Parreiras Martins, Maria Elisa Souza Silva, Claudio Rodrigues Leles, Mauro Henrique Nogueira Guimarães Abreu
OBJECTIVES: To describe consumer expenditure on opioids prescribed by dentists in Brazil during a 12-month period. METHODS: We surveyed individual dispensed prescriptions of opioids in private pharmacies from October 2012 to September 2013. A descriptive analysis of costs included a calculation of the overall and mean maximum price to consumers. Monetary costs were converted from local currency units (Brazilian Real - BRL) to international dollars using purchasing power parity (PPP) exchanging rates...
July 3, 2017: Journal of Public Health Dentistry
https://www.readbyqxmd.com/read/28661836/no-price-pressure-on-orphan-drugs-yet
#7
Ed Silverman
Sales of orphan drugs are forecast to grow 11% over the next five years, to $209 billion. That growth rate is twice as fast as the expected increase in sales of all other prescription medicines. They may account for more than 21% of brand-name prescription drug sales by 2022.
June 2017: Managed Care
https://www.readbyqxmd.com/read/28661288/the-prescription-drug-pricing-moment-using-public-health-analysis-to-clarify-the-fair-competition-debate-on-prescription-drug-pricing-and-consumer-welfare
#8
Ann Marie Marciarille
Fair competition law and public health law talk past each other when discussing pharmaceutical pricing and distribution. The former cannot agree on the relevant definition of consumer welfare. The latter does not fully comprehend the highly complex but inherently collective nature of pharmaceutical drug acquisition in the United States. This essay proposes to inject public health discourse into this debate to enrich it, focus it, and render it more accessible to those who must live by its outcome.
March 2017: Journal of Law, Medicine & Ethics: a Journal of the American Society of Law, Medicine & Ethics
https://www.readbyqxmd.com/read/28651591/the-cost-of-systemic-corticosteroid-induced-morbidity-in-severe-asthma-a-health-economic-analysis
#9
L E Barry, J Sweeney, C O'Neill, D Price, L G Heaney
BACKGROUND: Treatment of severe asthma may include high dose systemic-steroid therapy which is associated with substantial additional morbidity. This study estimates the additional healthcare costs associated with steroid-induced morbidity by comparing three patients groups: those with severe asthma, moderate asthma and no asthma. METHODS: Patients with severe asthma (n = 808, GINA step 5 treatment) were matched by age and gender with patients with mild/moderate asthma (n = 3,975, GINA step 2 and 3 treatment) and a non-asthma control cohort (with a diagnosis of rhinitis; n = 2,412) from the Optimum Patient Care Research Database (OPCRD), a nationally representative primary care database...
June 26, 2017: Respiratory Research
https://www.readbyqxmd.com/read/28648319/prediction-of-change-in-prescription-ingredient-costs-and-co-payment-rates-under-a-reference-pricing-system-in-south-korea
#10
Ji Haeng Heo, Karen L Rascati, Eui-Kyung Lee
BACKGROUND: The reference pricing system (RPS) establishes reference prices within interchangeable reference groupings. For drugs priced higher than the reference point, patients pay the difference between the reference price and the total price. OBJECTIVES: To predict potential changes in prescription ingredient costs and co-payment rates after implementation of an RPS in South Korea. METHODS: Korean National Health Insurance claims data were used as a baseline to develop possible RPS models...
May 2017: Value in Health Regional Issues
https://www.readbyqxmd.com/read/28625684/brand-medications-and-medicare-part-d-how-eye-care-providers-prescribing-patterns-influence-costs
#11
Paula Anne Newman-Casey, Maria A Woodward, Leslie M Niziol, Paul P Lee, Lindsey B De Lott
PURPOSE: To quantify costs of eye care providers' Medicare Part D prescribing patterns for ophthalmic medications and to estimate the potential savings of generic or therapeutic drug substitutions and price negotiation. DESIGN: Retrospective cross-sectional study. PARTICIPANTS: Eye care providers prescribing medications through Medicare Part D in 2013. METHODS: Medicare Part D 2013 prescriber public use file and summary file were used to calculate medication costs by physician specialty and drug...
June 16, 2017: Ophthalmology
https://www.readbyqxmd.com/read/28606975/drivers-of-expenditure-on-primary-care-prescription-drugs-in-10-high-income-countries-with-universal-health-coverage
#12
COMPARATIVE STUDY
Steven G Morgan, Christine Leopold, Anita K Wagner
BACKGROUND: Managing expenditures on pharmaceuticals is important for health systems to sustain universal access to necessary medicines. We sought to estimate the size and sources of differences in expenditures on primary care medications among high-income countries with universal health care systems. METHODS: We compared data on the 2015 volume and cost per day of primary care prescription drug therapies purchased in 10 high-income countries with various systems of universal health care coverage (7 from Europe, in addition to Australia, Canada and New Zealand)...
June 12, 2017: CMAJ: Canadian Medical Association Journal, Journal de L'Association Medicale Canadienne
https://www.readbyqxmd.com/read/28596826/field-evaluation-of-the-efficacy-of-common-anthelmintics-used-in-the-control-of-gastrointestinal-nematodes-of-sheep-in-dabat-district-northwest-ethiopia
#13
Zewdu Seyoum, Yitayew Demessie, Basazinew Bogale, Achenef Melaku
BACKGROUND: Gastrointestinal nematode (GIN) infections are the main impediments that restrict the welfare and productivity of small ruminant in the world. Effective management of GINs in grazing sheep relies heavily on the use of highly efficacious anthelmintic drugs. However, anthelmintic resistance is becoming a significant concern in the world, and this phenomenon severely threatens the potential utilisation of this control strategy. Therefore, this study was conducted 1) to evaluate the efficacy of commonly used anthelmintic on GINs in naturally infected sheep and 2) to assess the farmers' perception on anthelmintics utilisation practices in Dabat district, Northwest Ethiopia...
2017: Irish Veterinary Journal
https://www.readbyqxmd.com/read/28591520/targeting-unconscionable-prescription-drug-prices-maryland-s-anti-price-gouging-law
#14
Jeremy A Greene, William V Padula
Why, in the early 21st century, are so many drugs that were cheaply available in the 20th century becoming prohibitively expensive? The past few years have seen a series of dramatic price hikes on essential off-patent medications, from albendazole to albuterol, digoxin to naloxone, Daraprim to..
July 13, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/28558108/association-of-prescription-drug-price-rebates-in-medicare-part-d-with-patient-out-of-pocket-and-federal-spending
#15
Stacie B Dusetzina, Rena M Conti, Nancy L Yu, Peter B Bach
The increasing cost of prescription drugs is a burden for patients and threatens the financial stability of the US health care system. Rebates are a form of price concession paid by a pharmaceutical manufacturer to the health plan sponsor or the pharmacy benefit manager working on the plan's behalf. Proponents argue that rebates result from vigorous negotiations that help lower overall drug costs. Critics argue that rebates have perversely increased the costs patients pay out of pocket, as well as the costs for Medicare as a whole...
May 30, 2017: JAMA Internal Medicine
https://www.readbyqxmd.com/read/28549568/using-visual-analytics-for-presenting-comparative-information-on-new-drugs
#16
Jean-Baptiste Lamy, Hélène Berthelot, Madeleine Favre, Adrien Ugon, Catherine Duclos, Alain Venot
OBJECTIVE: When a new drug is marketed, physicians must decide whether they will consider it for their future practice. However, information about new drugs can be biased or hard to find. In this work, our objective was to study whether visual analytics could be used for comparing drug properties such as contraindications and adverse effects, and whether this visual comparison can help physicians to forge their own well-founded opinions about a new drug. MATERIALS AND METHODS: First, an ontology for comparative drug information was designed, based on the expectations expressed during focus groups comprised of physicians...
July 2017: Journal of Biomedical Informatics
https://www.readbyqxmd.com/read/28536176/cost-of-alteplase-has-more-than-doubled-over-the-past-decade
#17
Dawn Kleindorfer, Joseph Broderick, Bart Demaerschalk, Jeffrey Saver
BACKGROUND AND PURPOSE: Intravenous alteplase (tissue-type plasminogen activator) has been shown to be cost-effective because of savings in long-term disability. In October of 2005, an increased DRG payment to hospitals for alteplase-treated stroke patients was introduced. We sought to describe the trends in the cost of alteplase over time, in comparison to trends in hospital reimbursement in the United States. METHODS: Using publicly available information on the Centers for Medicare and Medicaid Services (CMS) website (www...
July 2017: Stroke; a Journal of Cerebral Circulation
https://www.readbyqxmd.com/read/28533252/national-trends-in-prescription-drug-expenditures-and-projections-for-2017
#18
Glen T Schumock, Edward C Li, Michelle D Wiest, Katie J Suda, JoAnn Stubbings, Linda M Matusiak, Robert J Hunkler, Lee C Vermeulen
PURPOSE: Historical trends and factors likely to influence future pharmaceutical expenditures are discussed, and projections are made for drug spending in 2017 in nonfederal hospitals, clinics, and overall (all sectors). METHODS: Drug expenditure data through calendar year 2016 were obtained from the QuintilesIMS National Sales Perspectives database and analyzed. Other factors that may influence drug spending in hospitals and clinics in 2017, including new drug approvals and patent expirations, were also reviewed...
May 22, 2017: American Journal of Health-system Pharmacy: AJHP
https://www.readbyqxmd.com/read/28520697/prescription-drug-prices-in-the-us
#19
(no author information available yet)
No abstract text is available yet for this article.
May 22, 2017: Medical Letter on Drugs and Therapeutics
https://www.readbyqxmd.com/read/28491312/neuroleptic-malignant-syndrome-following-catatonia-vigilance-is-the-price-of-antipsychotic-prescription
#20
Thomas J Reilly, Sean Cross, David M Taylor, Richard Haslam, Sophie C Tomlin, Benjamin Gaastra
OBJECTIVES: To describe a case of neuroleptic malignant syndrome following antipsychotic treatment of catatonia, highlighting the potentially serious complications of this rare adverse drug reaction. METHODS: We present a case report of a patient who developed this syndrome with various sequelae. RESULTS: The patient developed neuroleptic after being treated with lorazepam and olanzapine for catatonia. He subsequently developed the complications of rhabdomyolysis, acute kidney injury, pulmonary embolism, urinary retention and ileus...
2017: SAGE open medical case reports
keyword
keyword
109178
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"